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Abstract
Background: People with cystic fibrosis (CF) may work in healthcare settings risking nosocomial pathogen
acquisition. The aim of this study was to determine the incidence of methicillin-resistant Staphylococcus aureus
(MRSA) infection in adult healthcare workers with CF (HCWcf).
Methods: Data was collected in this observational study on MRSA acquisition from 405 CF patients attending
an adult CF centre in Australia between 2001–2012. Demographic and clinical characteristics were compared
between HCWcf and non-HCWcf. A sub-analysis was subsequently performed to compare demographic and clinical
characteristics between those patients (HCWcf versus non-HCWcf) that acquired MRSA. We also investigated rates of
chronic MRSA infection and the outcome of eradication treatment in HCWcf.
Results: A higher proportion of HCWcf acquired MRSA [n = 10/21] compared to non-HCWcf [n = 40/255] (P <0.001). The
odds of MRSA acquisition were 8.4 (95 % CI, 3.0 – 23.4) times greater in HCWcf than non-HCWcf. HCWcf with MRSA
were older (P = 0.02) and had better lung function (P = 0.009), yet hospitalisation rates were similar compared
to non-HCWcf with MRSA. Chronic MRSA infection developed in 36/50 CF patients (HCWcf, n = 6; non-HCWcf,
n = 30), with eradication therapy achieved in 5/6 (83 %) HCWcf.
Conclusions: The rate of MRSA incidence was highest in HCWcf and the workplace is a possible source of
acquisition. Vocational guidance should include the potential for MRSA acquisition for CF patients considering
healthcare professions.
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Background
Cystic fibrosis (CF) is the most common, life-limiting
genetic disease in the Caucasian population. Recent
studies predicted median survival of people with CF to
increase beyond 50 years [1, 2]. Consequently, these
individuals have the opportunity to pursue careers, in-
cluding training and employment in health-related fields.
A survey reported that ~7 % of adults with CF work in
healthcare professions in the UK [3].
Methicillin-resistant Staphylococcus aureus (MRSA)
is a major endemic pathogen in many hospitals posing
an important source of colonisation for staff with ~5 %
of healthcare workers developing non-fatal clinical
MRSA infections such as of the skin or soft tissue, or
life-threatening infections in at risk patients [4, 5]. In
patients with CF, chronic airway infection with MRSA
has been associated with poorer clinical outcomes [6, 7]
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The main aim of this study was to determine and com-
pare acquisition of MRSA amongst adult healthcare
workers with CF (HCWcf) and non-HCWcf. Rates of
chronic MRSA infection and the outcome of eradication
therapy were also investigated.
Methods
Study design
Of the more than 400 adults with CF in Queensland
(Australia), ~70 % receive their care at The Prince Charles
Hospital (TPCH), one of the largest adult CF centres in
the Southern Hemisphere. This study included CF pa-
tients (≥18 years, n = 405), who attended the adult CF
Centre, between 2001 and 2012. Ethics approval for this
project was granted by The Prince Charles Hospital
Human and Research Ethics Committee, Metro North
Hospital and Health Service, Brisbane, Queensland,
Australia (HREC/13/QPCH/51).
Figure 1 describes the design of this study. Briefly,
patients with CF were stratified into one of two
groups depending on whether they were a HCWcf or
a non-HCWcf. Each group was further sub-divided
into positive or negative for MRSA based on sputum
culture results.
A healthcare worker was defined as a person who
worked or undertook a clinical placement within a
healthcare facility (e.g. hospital, pharmacy) and had fre-
quent, direct patient contact. This group also comprised
veterinarians as it is recognised that people with animal
contact might have a greater chance of MRSA acquisi-
tion [9].
MRSA acquisition
TPCH Adult CF Centre database of all respiratory micro-
biology was reviewed and positive MRSA infections were
collated. All cases of MRSA acquisition were identified
and the date of MRSA acquisition was defined as the first
positive sputum culture recorded by the hospital micro-
biology laboratory. If a person was MRSA positive (i) at
the start of the study period in 2001 (n = 12), or (ii) when
transferred to care at TPCH (n = 6), the patient’s previous
hospital records were reviewed to determine the date of
acquisition. All patients included in this study acquired
MRSA between 1998 and 2012.
Clinical data
Clinical data were collected from medical records and
sputum microbiology was determined from the TPCH
CF database, where available. Demographics and clinical
parameters (i.e. age, gender, forced expiratory volume in
one second percent [FEV1%] predicted, pancreatic suffi-
ciency status, hospitalisation days and admissions and
details of Pseudomonas aeruginosa (P. aeruginosa) infec-
tion were determined for the entire cohort. Data for
MRSA positive patients corresponded to the date of ini-
tial acquisition. In the non-MRSA group, data was col-
lected at 2012 and excluded those who had been
Fig. 1 Cross-sectional observational study design. This study identified patients with CF, who were MRSA culture positive and were either a
HCWcf or a non-HCWcf. Abbreviations: HCWcf, adult healthcare workers with CF; non-HCWcf, adult non-healthcare workers with CF; TPCH, The
Prince Charles Hospital. *Multiresistant MRSA was detected in 5 HCWcf and 30 non-HCWcf. Non-multiresistant MRSA was detected in 5 HCWcf
and 10 non-HCWcf
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transplanted, were deceased or had not been a clinic pa-
tient for the full 2 years prior to 2012 (Fig. 1).
Results of peripheral skin screening swabs (nose, axilla
and groin) collected subsequent to MRSA respiratory ac-
quisition were reviewed, with individuals recorded as either
positive or negative for peripheral MRSA colonisation.
Classification of MRSA and eradication therapy
At the time of data collection, microbiology laboratories in
Queensland differentiated isolates phenotypically as multi-
resistant MRSA (mMRSA) or non-mMRSA (nmMRSA)
strains. Briefly, mMRSA was identified if an isolate was
resistant to all β-lactam antibiotics and to three or more
non-β-lactam agents (e.g. clindamycin, tetracycline, rifam-
picin). An isolate was defined as nmMRSA if resistance to
all β-lactam agents was apparent but susceptibility to two
or more non-β-lactam antibiotics was identified.
Patients positive for airways MRSA were categorised as
intermittently colonised or chronically infected according
to a modification of the ‘Leeds Criteria’ defined for P.
aeruginosa [10]. Briefly, intermittent MRSA colonisation
was identified when ≤50 % of the months that respiratory
samples were collected were culture positive (including
patients who had one positive culture during the study
period). Chronic MRSA infection was identified when
>50 % of samples collected were culture positive.
As a subset analysis, longitudinal data for the MRSA
positive HCWcf was collected to determine treatment
outcomes. The first-line eradication regimen utilised at
TPCH to treat MRSA infection of the CF airways was
6 months combination therapy of oral rifampicin 600 mg
daily and sodium fusidate 500 mg twice daily after consid-
ering in vitro antibiotic susceptibility results [11]. Nasal
and cutaneous decontamination was also undertaken if
peripheral colonisation was detected. Eradication of
MRSA, following 6 months of treatment was defined as
six consecutive negative samples over a minimum period
of 12 months.
Data analysis
Demographics and clinical data were compared between
groups using an independent t-test or Mann-Whitney
test for continuous data and a Chi-squared test with
Yates continuity correction or Fishers-Exact test for cat-
egorical data, as appropriate. Simple univariable and
multivariable logistic regression analysis was performed
to identify predictors of MRSA infection. Variables with
P <0.1 were included in a multivariable model. Data
analysis was performed using Stata (v14, StataCorp) or
SPSS (v22). A P value of less than 0.05 was considered
statistically significant.
Results
Patient characteristics for the entire cohort
During the study period, 21/405 (5 %) patients with CF
worked in a healthcare discipline (Fig. 1). The vocations
were comprised of medicine (n = 4); nursing/nursing as-
sistant (n = 4); physiotherapist/assistant (n = 4); radiog-
rapher (n = 2); theatre attendant (n = 2); paramedic (n = 2);
pharmacist (n = 1); phlebotomist (n = 1); small-animal vet-
erinary surgeon (n = 1). All of the CF patients working in
healthcare settings had frequent non-CF patient contact.
When we compared the demographic and clinical data
between the non-HCWcf (n = 255) and HCWcf (n = 21),
a statistical difference was only observed for lung func-
tion (Table 1). The FEV1 % predicted was higher among
the HCWcf (median 72.1 % predicted) compared to the
non-HCWcf (58.5 % predicted) [P = 0.003].
MRSA acquisition
Fifty patients with CF acquired MRSA (HCWcf, n = 10;
non-HCWcf, n = 40, Fig. 1). A significantly higher pro-
portion of HCWcf (n = 10/21, 48 %) acquired MRSA
compared to non-HCWcf (n = 40/255, 16 %) (P <0.001).
In a univariable logistic regression, the odds of MRSA
acquisition were higher in the HCWcf compared to the
non-HCWcf (Table 2). After adjusting for age and the
number of hospital admissions in the previous 2 years
(in a multivariable logistic regression) the odds of MRSA
acquisition were 8.4 times higher in the HCWcf versus
the non-HCWcf (Table 2).
Table 3 describes and compares the demographic, clin-
ical and microbiological characteristics of both groups of
MRSA positive patients (HCWcf versus non-HCWcf) at
Table 1 Demographics and Clinical Characteristics of HCWcf and non-HCWcf
Characteristics HCWcf Non-HCWcf P value
No.a No.a
Age (years), median (IQR) 21 29 (23–37) 254 27 (21–34) 0.116
FEV1% predicted, median (IQR) 20 72.1 (61.3–90.9) 239 58.5 (37.9–73.1) 0.003
Number of hospitalisations in previous 2 years, median (IQR) 19 1 (0–3) 247 2 (0–5) 0.374
Number of hospital days, median (IQR) 19 9 (0–27) 246 16 (0–52) 0.251
Pancreatic insufficient, n (%) 21 16 (76) 254 221 (87) 0.177
P. aeruginosa infection, n (%) 20 15 (75) 255 224 (88) 0.157
a21 HCWcf and 255 non-HCWcf included in the analysis. Data missing on some occasions
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the time of acquisition. HCWcf were significantly older
(P = 0.02) and had better lung function (FEV1 % pre-
dicted, P = 0.009) than non-HCWcf at the time of MRSA
acquisition. Pancreatic sufficiency was more common
within the HCWcf group compared to non-HCWcf
(P = 0.048). There was no difference in sex (P = 0.494), P.
aeruginosa infection status (P = 0.086) or hospital days
(P = 0.177) and admissions (P = 0.23) between the two
groups. Furthermore, no difference in the acquisition
of either mMRSA or nmMRSA was observed between
the groups (P = 0.143).
Chronicity of infection and treatment outcomes in a
subset of individuals
Seventy-two percent of patients, who acquired MRSA
(n = 36/50), subsequently developed chronic infection as
defined by the Leeds Criteria. There was no statistical
difference between rates of chronic MRSA infection
when the two MRSA positive cohorts (HCWcf versus
non-HCWcf) were compared (P = 0.44). Eleven of 42
(26 %) CF patients with MRSA airway isolation were also
peripherally colonised with the bacterium (a documented
skin swab result was not available for 8 patients). No
association between colonisation of the skin by MRSA
and HCWcf (22 %) or non-HCWcf (27 %) was detected
(P = 1.0, Table 3).
All HCWcf with chronic MRSA respiratory infection
(n = 6) received eradication therapy with successful
eradication occurring in 5/6 (83 %) patients (Table 4).
The remaining HCWcf (n = 4) had intermittent colonisa-
tion and cleared MRSA spontaneously.
Discussion
The number of adults with CF is rapidly increasing
with two thirds of this population in paid employ-
ment in Australia [12]. However, certain careers may
increase the risk of exposure to harmful respiratory
pathogens [13, 14]. It was also previously demonstrated
that ~4.6 % of screened healthcare workers are colonised
by MRSA [4]. In our study we present novel data investi-
gating the association between working within a health-
care profession and the potential for MRSA acquisition in
CF patients. We found that people with CF, who work in a
healthcare profession, are at a greater risk of acquiring
MRSA when compared to those who are not employed in
this sector.
MRSA acquisition in people with CF differs both lo-
cally and internationally. For example, in Northern
America the prevalence of MRSA exceeds 20 % of the
total CF population [15], whereas in Australia, the
point-prevalence in adults was reported as 4 % in 2013
[16]. Furthermore, at TPCH a decline in the annual
prevalence of MRSA from 8.3 % in 2001 to 3.8 % in
2012 was observed (data not shown). It was previously
reported that MRSA infection of the CF airways was as-
sociated with lower lung function in children and young
people up to 21 years [7, 17], increased rates of hospita-
lisations and antibiotic requirements and worse survival
compared to uninfected patients [6]. Therefore, it is
Table 2 Regression analysis of factors associated with MRSA
acquisition
Univariable Odds ratio (95 % CI) P value
Healthcare worker 4.87 (1.95–12.27) 0.001
Age (per 5 years) 0.79 (0.65–0.97) 0.026
FEV1% predicted (per 5 %) 0.98 (0.91–1.05) 0.514
Number of hospital admissions in
previous 2 years (per admission)
1.11 (1.01–1.22) 0.028
Multivariable Odds ratio (95 % CI) P value
Healthcare worker 8.36 (2.99–23.39) <0.001
Age (per 5 years) 0.78 (0.61–0.99) 0.039
Number of hospital admissions in
previous 2 years (per admission)
1.13 (1.03–1.25) 0.011
Table 3 Demographics and Clinical Data of MRSA positive patients
Characteristics HCWcf Non-HCWcf P value
No.a No.a
Male, n (%) 10 5 (50) 40 25 (63) 0.494
Age (years), median (IQR) 10 28 (26–37.5) 39 22 (19–27) 0.02
FEV1 % predicted, median (IQR) 10 72.4 (62.2–90.9) 36 48.7 (33.2–64.8) 0.009
Pancreatic insufficient, n (%) 10 7 (70) 40 38 (95) 0.048
P. aeruginosa infection, n (%) 10 7 (70) 40 37 (93) 0.086
Hospitalisations in 2 years prior, median (IQR) 9 3 (1–4) 32 4 (2–6) 0.23
Hospital days in 2 years prior, median (IQR) 9 27 (4–37) 31 49 (19–76) 0.177
Peripheral colonisation, n (%) 9 2 (22) 33 9 (27) 1.0
mrMRSA, n (%) 10 5 (50) 40 30 (75) 0.143
Abbreviations: mrMRSA, multiresistant MRSA
a10 HCWcf and 40 non-HCWcf included in this analysis. Data missing on some occasions
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important to identify and monitor MRSA infection in
CF patients.
When the clinical characteristics were compared be-
tween HCWcf and non-HCWcf at the time of MRSA ac-
quisition, it was observed that the HCWcf were healthier
(indicated by better lung function) despite being older than
the non-HCWcf. Whilst it is difficult to determine the rea-
sons for better lung function of the HCWcf, the difference
may reflect higher rates of pancreatic sufficiency, suggest-
ive of a milder cohort of patients. Additionally, a healthier
cohort may be attracted to study as healthcare profes-
sionals and undertake the rigors of gaining tertiary and/or
professional qualifications.
Increased hospitalisations are a recognised risk factor
for MRSA acquisition within a CF population [14].
There was no difference in the number of admissions
or inpatient days between HCWcf and non-HCWcf
with airways MRSA. Although cautious interpretation
is required, we speculate that MRSA acquisition amongst
the HCWcf may have occurred as a result of occupational
exposure. However, it should be noted that our analyses
did not extend to outpatient clinic or non-healthcare
associated exposures and we cannot completely exclude
MRSA acquisition during periods of hospitalisation; thus
additional work is required to confirm our hypothesis.
Employment within a CF Centre theoretically poses
one of the greatest risks to a HCWcf because of the
strong body of evidence that has demonstrated the in-
creased risk of cross-infection with other CF pathogens
(including P. aeruginosa, Burkholderia cepacia complex
and Mycobacterium abscessus) [14, 18–20]. However, an
earlier case report of a HCWcf at TPCH (this patient is
also included in the current study [patient #5, Table 4])
observed that MRSA respiratory acquisition was possibly
the result of contact with non-CF patients at work [21].
Our study further highlights that healthcare employment,
which involves frequent patient contact poses inherent
risks to the person with CF. Previous studies demon-
strated that MRSA is transmitted by direct person-to-
person contact or via indirect contact with contaminated
fomites [22, 23]. Furthermore, there is evidence indicating
that Staphylococci may be capable of surviving in aerosol-
ised particles within the respirable range [24, 25]. Studies
are warranted to investigate the possibility of S. aureus
transmission via the airborne route as was previously
shown for P. aeruginosa [26].
There is a lack of evidence surrounding the role of
eradication treatment of MRSA in CF and the most ap-
propriate protocol to use [27]. In healthcare workers, it
was also reported that decolonisation therapies varied
but that eradication therapy was successful in 88 % of
those treated [4]. At TPCH, factors used to determine
the initiation of MRSA eradication treatment include
chronicity of airways infection, potential adherence to
the prolonged treatment regimen, clinical status and
type of employment. In the current study, 72 % of CF
patients developed chronic MRSA airways infection in-
cluding 60 % of HCWcf. In non-CF healthcare workers,
clinical infection with MRSA is infrequent with chronic
infection developing occasionally (e.g. chronic MRSA
sinusitis) [4, 28]. We have previously shown that pro-
longed treatment with rifampicin and sodium fusidate
can eradicate chronic respiratory MRSA infection in a
small number of adult CF patients [11] and in the
current study 83 % of HCWcf achieved eradication with
the same regimen. However, further prospective trials
are needed to determine the best antibiotics to use, the
duration of therapy and the effect on CF patient survival.
It is also unclear if newly acquired MRSA infections
should be treated in CF; however, preliminary results of
Table 4 Types of infection and treatment outcomes among the 10 adult healthcare workers with CF (HCWcf) and methicillin-resistant
Staphylococcus aureus (MRSA) airways infection
HCWcf
(n)
Type of infectiona Antibiotic treatmenta Outcome
Rifampicin Sodium fusidate Linezolid Eradicated Chronic Spontaneously cleared
1 Chronic X X X
2 Chronic X X X
3 Chronic X X X
4 Chronic X X X
5 Chronic X X X
6b Chronic X X X X




aMedian (IQR) time to initiation of treatment was 52 (37.5–77) days
bPatient was prescribed 6 weeks of linezolid following 6 months of rifampicin plus sodium fusidate
cPatient commenced eradication treatment but self-elected to cease after 3 weeks of therapy because of intolerance
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the STAR-Too trial (NCT01349192) demonstrated that
an eradication regimen for new MRSA airways colonisa-
tion was microbiologically efficacious and reduced pul-
monary exacerbations in patients treated with combination
oral and topical therapies coupled with environmental de-
contamination compared to a control observational group
[29]. Evidence from our study indicated that only a quarter
of CF patients with MRSA airways infection were also
peripherally colonised with the bacterium. Therefore,
larger studies are required for a risk-benefit analysis of
topical decolonisation treatments (which can cause hyper-
sensitivity reactions) in all patients with MRSA respiratory
colonisation.
Limitations of this retrospective study include that a
small number of patients were studied. However this re-
flects epidemiological data, which demonstrates that
MRSA infection remains low in Australia compared to
other recognised CF pathogens. Furthermore, annual ac-
quisition of MRSA at TPCH has remained consistently
low over the past decade (0–5 new cases per annum; in-
cidence rate: 0–2.3 %; data not shown). Also, the results
of this study were based on evidence collected from a
single CF care centre in Australia. Although this centre
cares for ~70 % of CF adults in Queensland, additional
multi-centre studies, in other clinical settings where
rates of MRSA endemicity vary, are required to confirm
the findings of our study.
Conclusions
To our knowledge this is the first study to demonstrate
that acquisition of MRSA occurs more frequently
amongst HCWcf than non-HCWcf. These data suggest
that occupational exposure may increase the risk of
MRSA acquisition for CF patients. Based on these find-
ings we recommend that vocational guidance be pro-
vided to persons with CF who are considering pursuing
a career in the healthcare industry. Likewise, there is an
urgent need for the establishment of guidelines for CF
Centres, healthcare training institutions and hospitals
for the management of CF patients training and/or
working in healthcare.
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